Immuron

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Analyst Reports

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

Why Immuron?

Home

Plus Jakarta Sans

Dear Shareholders,

We're happy to report that Immuron has achieved record sales up to the FY ending June 30, 2025, and is on track to exceed FY24 first quarter sales. Notably, the US tariffs on pharmaceutical products are not expected to impact us significantly. We also have exciting updates on several key projects:

- Travelan® Clinical Study results are expected in October 2025.
- IMM-529 Regulatory Milestone: IND application to the U.S. FDA planned for mid-October 2025.
- ProIBS® Commercial Launch on track for Q4 of 2025.
- IMM-986 Pre-Clinical Progress: Initial research studies anticipated by year-end 2025.

Our CEO, Steven Lydeamore, has provided a comprehensive overview in the recent announcement, outlining our progress and upcoming milestones. We're open to any questions you may have about our projects. Stay informed and engaged in our journey towards success.

Sincerely,
Steve Lydeamore

Dear Shareholders, We're happy to report that Immuron has achieved record sales up to the FY ending June 30, 2025, and is on track to exceed FY24 first quarter sales. Notably, the US tariffs on pharmaceutical products are not expected to impact us significantly. We also have exciting updates on several key projects: - Travelan® Clinical Study results are expected in October 2025. - IMM-529 Regulatory Milestone: IND application to the U.S. FDA planned for mid-October 2025. - ProIBS® Commercial Launch on track for Q4 of 2025. - IMM-986 Pre-Clinical Progress: Initial research studies anticipated by year-end 2025. Our CEO, Steven Lydeamore, has provided a comprehensive overview in the recent announcement, outlining our progress and upcoming milestones. We're open to any questions you may have about our projects or financial outlook. Stay informed and engaged in our journey towards success. Sincerely, [Your Name] Management Team